abcam

Product datasheet

Anti-Tau (phospho S199) antibody ab4749

★★★★★ 1 Abreviews 7 References 画像数 3

製品の概要

製品名 Anti-Tau (phospho S199) antibody

製品の詳細 Rabbit polyclonal to Tau (phospho S199)

由来種 Rabbit

特異性 The specificity of this antibody refers to P10636-8.

アプリケーション 適用あり: IHC-P, WB

種交差性 交差種: Mouse, Human, African green monkey

交差が予測される動物種: Rat 🔷

免疫原 Synthetic peptide corresponding to Human Tau (phospho S199).

Database link: P10636-8

ポジティブ・コントロール IHC-P: Mouse brain tissue, human brain tissue. WB: African green monkey kidney.

The Life Science industry has been in the grips of a reproducibility crisis for a number of years.

Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets

your needs before purchasing.

If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be

found below, along with publications, customer reviews and Q&As

製品の特性

特記事項

製品の状態 Liquid

保存方法 Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

パッファー pH: 7.30

Preservative: 0.05% Sodium azide

Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA

精製度 Immunogen affinity purified

特記事項(精製) Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has

been negatively preadsorbed using a non-phosphopeptide corresponding to the site of

phosphorylation to remove antibody that is reactive with non-phosphorylated tau. The final product is generated by affinity chromatography using a tau-derived peptide that is phosphorylated at

serine 199.

1

ポリ/モノ ポリクローナル

アイソタイプ IgG

アプリケーション

The Abpromise guarantee <u>Abpromise保証は、</u>次のテスト済みアプリケーションにおけるab4749の使用に適用されますアプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション	Abreviews	特記事項
IHC-P		1/20 - 1/200.
WB	*** <u>*</u> (1)	1/1000. Detects a band of approximately 60 kDa.

ターゲット情報

機能

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

組織特異性

Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

関連疾患

Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presentile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.

Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles

and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

配列類似性

Contains 4 Tau/MAP repeats.

発生段階

Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.

ドメイン

The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.

翻訳後修飾

Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking

Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.


細胞内局在

Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

製品の状態

There are 9 isoforms produced by alternative splicing.


画像



Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections) - Anti-Tau (phospho S199) antibody (ab4749)

Paraffin embedded human brain tissue (right) stained for Tau using ab4749 at 1/100 dilution in immunohistochemical analysis.


Negative control without primary antibody (left).



Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections) - Anti-Tau (phospho S199) antibody (ab4749)

Paraffin embedded mouse brain tissue (right) stained for Tau using ab4749 at 1/100 dilution in immunohistochemical analysis.

Negative control without primary antibody (left).



Western blot - Anti-Tau (phospho S199) antibody (ab4749)

Cell extracts from African green monkey kidney (CV-1) cells, stably expressing human four repeat tau and a protein phosphatase inhibitor, were resolved by SDS-PAGE on a 10% Tris-glycine gel. The proteins were transferred to nitrocellulose. Membranes were incubated with 0.50 μg/mL anti-phospho tau [pS199] (ab4749), following prior incubation in the absence (a) or presence of the peptide immunogen (b), or the nonphosphopeptide corresponding to the tau phosphopeptide (c). Cell extracts from African green monkey kidney (CV-1) cells, stably expressing human four repeat tau and a protein phosphatase inhibitor, were resolved by SDS-PAGE on a 10% Tris-glycine gel. The proteins were transferred to nitrocellulose. Membranes were incubated with 0.50 μg/mL anti-phospho tau [pS199] (ab4749), following prior incubation in the

absence (a) or presence of the peptide immunogen (b), or the nonphosphopeptide corresponding to the tau phosphopeptide (c).

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- · We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit https://www.abcam.co.jp/abpromise or contact our technical team.

Terms and conditions

• Guarantee only valid for products bought direct from Abcam or one of our authorized distributors